Antimicrobial Therapeutics Market Research Report Information By Application (Antiviral, Antibacterial, Antifungal, and Antiparasitic), By End User (Pharmacies, Hospitals and Clinics, and Research and Academic Institutes), and By Region (North America, Europe, Asia-Pacific, and Rest of The World) – Market Forecast Till 2032

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION

6.1. Overview

6.2. Antiviral

6.3. Antibacterial

6.4. Antifungal

6.5. Antiparasitic

7. GLOBAL ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER

7.1. Overview

7.2. Pharmacies

7.3. Hospitals and clinics

7.4. Research and academic institutes

8. GLOBAL ANTIMICROBIAL THERAPEUTICS MARKET, BY REGION

8.1. Overview

8.2. North America

8.2.1. U.S.

8.2.2. Canada

8.3. Europe

8.3.1. Germany

8.3.2. France

8.3.3. U.K

8.3.4. Italy

8.3.5. Spain

8.3.6. Rest of Europe

8.4. Asia-Pacific

8.4.1. China

8.4.2. India

8.4.3. Japan

8.4.4. South Korea

8.4.5. Australia

8.4.6. Rest of Asia-Pacific

8.5. Rest of the World

8.5.1. Middle East

8.5.2. Africa

8.5.3. Latin America

9. COMPETITIVE LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Global Antimicrobial Therapeutics Market,

9.5. Competitive Benchmarking

9.6. Leading Players in Terms of Number of Developments in the Global Antimicrobial Therapeutics Market,

9.7. Key developments and Growth Strategies

9.7.1. New APPLICATION Launch/End User Deployment

9.7.2. Merger & Acquisitions

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix

9.8.1. Sales & Operating Income, 2022

9.8.2. Major Players R&D Expenditure. 2022

10. COMPANY PROFILES

10.1. AbbVie Inc.

10.1.1. Company Overview

10.1.2. Financial Overview

10.1.3. APPLICATIONs Offered

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Astellas Pharma Inc.

10.2.1. Company Overview

10.2.2. Financial Overview

10.2.3. APPLICATIONs Offered

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. Bavarian Nordic AS

10.3.1. Company Overview

10.3.2. Financial Overview

10.3.3. APPLICATIONs Offered

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. Biocidium Biopharmaceuticals Inc.

10.4.1. Company Overview

10.4.2. Financial Overview

10.4.3. APPLICATIONs Offered

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Bristol Myers Squibb Co.

10.5.1. Company Overview

10.5.2. Financial Overview

10.5.3. APPLICATIONs Offered

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. CADILA PHARMACEUTICALS LTD.

10.6.1. Company Overview

10.6.2. Financial Overview

10.6.3. APPLICATIONs Offered

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. CSL LTD.

10.7.1. Company Overview

10.7.2. Financial Overview

10.7.3. APPLICATIONs Offered

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. Emergent BioSolutions Inc.

10.8.1. Company Overview

10.8.2. Financial Overview

10.8.3. APPLICATIONs Offered

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. F. HOFFMANN LA ROCHE LTD.

10.9.1. Company Overview

10.9.2. Financial Overview

10.9.3. APPLICATIONs Offered

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. Gilead Sciences Inc.

10.10.1. Company Overview

10.10.2. Financial Overview

10.10.3. APPLICATIONs Offered

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

10.11. GlaxoSmithKline Plc

10.11.1. Company Overview

10.11.2. Financial Overview

10.11.3. APPLICATIONs Offered

10.11.4. Key Developments

10.11.5. SWOT Analysis

10.11.6. Key Strategies

10.12. Inovio Pharmaceuticals Inc.

10.12.1. Company Overview

10.12.2. Financial Overview

10.12.3. APPLICATIONs Offered

10.12.4. Key Developments

10.12.5. SWOT Analysis

10.12.6. Key Strategies

10.13. Johnson and Johnson Services Inc.

10.13.1. Company Overview

10.13.2. Financial Overview

10.13.3. APPLICATIONs Offered

10.13.4. Key Developments

10.13.5. SWOT Analysis

10.13.6. Key Strategies

10.14. Merck and Co. Inc.

10.14.1. Company Overview

10.14.2. Financial Overview

10.14.3. APPLICATIONs Offered

10.14.4. Key Developments

10.14.5. SWOT Analysis

10.14.6. Key Strategies

10.15. Mitsubishi Tanabe Pharma Corp.

10.15.1. Company Overview

10.15.2. Financial Overview

10.15.3. APPLICATIONs Offered

10.15.4. Key Developments

10.15.5. SWOT Analysis

10.15.6. Key Strategies

10.16. Novartis AG

10.16.1. Company Overview

10.16.2. Financial Overview

10.16.3. APPLICATIONs Offered

10.16.4. Key Developments

10.16.5. SWOT Analysis

10.16.6. Key Strategies

10.17. Novavax Inc.

10.17.1. Company Overview

10.17.2. Financial Overview

10.17.3. APPLICATIONs Offered

10.17.4. Key Developments

10.17.5. SWOT Analysis

10.17.6. Key Strategies

10.18. Pfizer Inc.

10.18.1. Company Overview

10.18.2. Financial Overview

10.18.3. APPLICATIONs Offered

10.18.4. Key Developments

10.18.5. SWOT Analysis

10.18.6. Key Strategies

10.19. Sanofi SA

10.19.1. Company Overview

10.19.2. Financial Overview

10.19.3. APPLICATIONs Offered

10.19.4. Key Developments

10.19.5. SWOT Analysis

10.19.6. Key Strategies

10.20. Wockhardt Ltd.

10.20.1. Company Overview

10.20.2. Financial Overview

10.20.3. APPLICATIONs Offered

10.20.4. Key Developments

10.20.5. SWOT Analysis

10.20.6. Key Strategies

11. APPENDIX

11.1. References

11.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL ANTIMICROBIAL THERAPEUTICS MARKET, SYNOPSIS, 2018-2032

TABLE 2 GLOBAL ANTIMICROBIAL THERAPEUTICS MARKET, ESTIMATES & FORECAST, 2018-2032 (USD BILLION)

TABLE 3 GLOBAL ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 4 GLOBAL ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 5 NORTH AMERICA ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 6 NORTH AMERICA ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 7 NORTH AMERICA ANTIMICROBIAL THERAPEUTICS MARKET, BY COUNTRY, 2018-2032 (USD BILLION)

TABLE 8 U.S. ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 9 U.S. ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 10 CANADA ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 11 CANADA ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 12 EUROPE ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 13 EUROPE ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 14 EUROPE ANTIMICROBIAL THERAPEUTICS MARKET, BY COUNTRY, 2018-2032 (USD BILLION)

TABLE 15 GERMANY ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 16 GERMANY ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 17 FRANCE ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 18 FRANCE ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 19 ITALY ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 20 ITALY ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 21 SPAIN ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 22 SPAIN ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 23 U.K ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 24 U.K ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 25 REST OF EUROPE ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 26 REST OF EUROPE ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 27 ASIA PACIFIC ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 28 ASIA PACIFIC ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 29 ASIA PACIFIC ANTIMICROBIAL THERAPEUTICS MARKET, BY COUNTRY, 2018-2032 (USD BILLION)

TABLE 30 JAPAN ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 31 JAPAN ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 32 CHINA ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 33 CHINA ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 34 INDIA ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 35 INDIA ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 36 AUSTRALIA ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 37 AUSTRALIA ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 38 SOUTH KOREA ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 39 SOUTH KOREA ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 40 REST OF ASIA-PACIFIC ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 41 REST OF ASIA-PACIFIC ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 42 REST OF WORLD ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 43 REST OF WORLD ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 44 REST OF WORLD ANTIMICROBIAL THERAPEUTICS MARKET, BY COUNTRY, 2018-2032 (USD BILLION)

TABLE 45 MIDDLE EAST ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 46 MIDDLE EAST ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 47 AFRICA ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 48 AFRICA ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 49 LATIN AMERICA ANTIMICROBIAL THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 50 LATIN AMERICA ANTIMICROBIAL THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL ANTIMICROBIAL THERAPEUTICS MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL ANTIMICROBIAL THERAPEUTICS MARKET

FIGURE 4 GLOBAL ANTIMICROBIAL THERAPEUTICS MARKET, SHARE (%), BY APPLICATION, 2022

FIGURE 5 GLOBAL ANTIMICROBIAL THERAPEUTICS MARKET, SHARE (%), BY END USER, 2022

FIGURE 6 GLOBAL ANTIMICROBIAL THERAPEUTICS MARKET, SHARE (%), BY REGION, 2022

FIGURE 7 NORTH AMERICA: ANTIMICROBIAL THERAPEUTICS MARKET, SHARE (%), BY REGION, 2022

FIGURE 8 EUROPE: ANTIMICROBIAL THERAPEUTICS MARKET, SHARE (%), BY REGION, 2022

FIGURE 9 ASIA-PACIFIC: ANTIMICROBIAL THERAPEUTICS MARKET, SHARE (%), BY REGION, 2022

FIGURE 10 REST OF THE WORLD: ANTIMICROBIAL THERAPEUTICS MARKET, SHARE (%), BY REGION, 2022

FIGURE 11 GLOBAL ANTIMICROBIAL THERAPEUTICS MARKET: COMPANY SHARE ANALYSIS, 2022 (%)

FIGURE 12 ABBVIE INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 13 ABBVIE INC.: SWOT ANALYSIS

FIGURE 14 ASTELLAS PHARMA INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 15 ASTELLAS PHARMA INC.: SWOT ANALYSIS

FIGURE 16 BAVARIAN NORDIC AS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 BAVARIAN NORDIC AS: SWOT ANALYSIS

FIGURE 18 BIOCIDIUM BIOPHARMACEUTICALS INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 BIOCIDIUM BIOPHARMACEUTICALS INC.: SWOT ANALYSIS

FIGURE 20 BRISTOL MYERS SQUIBB CO..: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 BRISTOL MYERS SQUIBB CO..: SWOT ANALYSIS

FIGURE 22 CADILA PHARMACEUTICALS LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 CADILA PHARMACEUTICALS LTD.: SWOT ANALYSIS

FIGURE 24 CSL LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 CSL LTD.: SWOT ANALYSIS

FIGURE 26 EMERGENT BIOSOLUTIONS INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 EMERGENT BIOSOLUTIONS INC.: SWOT ANALYSIS

FIGURE 28 F. HOFFMANN LA ROCHE LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 F. HOFFMANN LA ROCHE LTD.: SWOT ANALYSIS

FIGURE 30 GILEAD SCIENCES INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 GILEAD SCIENCES INC.: SWOT ANALYSIS

FIGURE 32 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 33 GLAXOSMITHKLINE PLC: SWOT ANALYSIS

FIGURE 34 INOVIO PHARMACEUTICALS INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 35 INOVIO PHARMACEUTICALS INC.: SWOT ANALYSIS

FIGURE 36 JOHNSON AND JOHNSON SERVICES INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 37 JOHNSON AND JOHNSON SERVICES INC.: SWOT ANALYSIS

FIGURE 38 MERCK AND CO. INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 39 MERCK AND CO. INC.: SWOT ANALYSIS

FIGURE 40 MITSUBISHI TANABE PHARMA CORP.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 41 MITSUBISHI TANABE PHARMA CORP..: SWOT ANALYSIS

FIGURE 42 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 43 NOVARTIS AG: SWOT ANALYSIS

FIGURE 44 NOVAVAX INC..: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 45 NOVAVAX INC: SWOT ANALYSIS

FIGURE 46 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 47 PFIZER INC.: SWOT ANALYSIS

FIGURE 48 SANOFI SA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 49 SANOFI SA: SWOT ANALYSIS

FIGURE 50 WOCKHARDT LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 51 WOCKHARDT LTD.: SWOT ANALYSIS